Journal of Antimicrobial Chemotherapy (2001) 47, 647-650
© 2001 The British Society for Antimicrobial Chemotherapy
Brief report |
Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus
Antimicrobial Research Centre and Division of Microbiology, University of Leeds, Leeds LS2 9JT, UK
Frequencies at which mutants resistant to fusidic acid and/or rifampicin arose in vitro were determined in Staphylococcus aureus strains including methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-intermediate resistant S. aureus (VISA) and hetero-VISA. The concentrations of fusidic acid (30 and 15 mg/L) and rifampicin (16 and 1 mg/L) used for selection were equal to the expected maximum and minimum serum concentrations after an oral regimen of rifampicin 900 mg od, together with fusidic acid 500 mg tds. Resistant mutants arose at a frequency of around 10-8 for selections with rifampicin, but were undetectable (frequency <10-11) for selections with fusidic acid. Mutants were not recovered (frequency <10-11) after selections in the presence of both fusidic acid and rifampicin at 30/16 and 15/1 mg/L. Our results suggest that these antibiotics, when used in combination, could have a wider role in the management of staphylococcal infections.
* Corresponding author. Tel: +44-113-233-5604; Fax: +44-113-233-5638; E-mail: i.chopra{at}leeds.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Miller, C. J. Dunsmore, C. W. G. Fishwick, and I. Chopra Linezolid and Tiamulin Cross-Resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase Center Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1737 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Vickers, A. J. O'Neill, and I. Chopra Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies J. Antimicrob. Chemother., August 1, 2007; 60(2): 269 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Murphy, S. Mullin, M. S. Osburne, J. van Duzer, J. Siedlecki, X. Yu, K. Kerstein, M. Cynamon, and D. M. Rothstein In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., March 1, 2006; 50(3): 827 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, J. Cui, R. Wang, X. Wang, K. Drlica, and X. Zhao Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance J. Antimicrob. Chemother., December 1, 2005; 56(6): 1172 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-L. Prunier and R. Leclercq Role of mutS and mutL Genes in Hypermutability and Recombination in Staphylococcus aureus J. Bacteriol., May 15, 2005; 187(10): 3455 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miller, C. Storey, W. J. Stubbings, A. M. Hoyle, J. K. Hobbs, and I. Chopra Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175) J. Antimicrob. Chemother., April 1, 2005; 55(4): 579 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Hurdle, A. J. O'Neill, E. Ingham, C. Fishwick, and I. Chopra Analysis of Mupirocin Resistance and Fitness in Staphylococcus aureus by Molecular Genetic and Structural Modeling Techniques Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4366 - 4376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wullt and I. Odenholt A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea J. Antimicrob. Chemother., July 1, 2004; 54(1): 211 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Oliva, A. J. O'Neill, K. Miller, W. Stubbings, and I. Chopra Anti-staphylococcal activity and mode of action of clofazimine J. Antimicrob. Chemother., March 1, 2004; 53(3): 435 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Hurdle, A. J. O'Neill, and I. Chopra The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden J. Antimicrob. Chemother., January 1, 2004; 53(1): 102 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill, I. Chopra, G. Bierbaum, A. Reipert, and F. Schaaff Lack of Evidence for Involvement of Hypermutability in Emergence of Vancomycin-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1484 - 1485. [Full Text] [PDF]
|
|
|
|
|
|
B. W. Mason, A. J. Howard, and J. T. Magee Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing J. Antimicrob. Chemother., April 1, 2003; 51(4): 1033 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Oliva, K. Miller, N. Caggiano, A. J. O'Neill, G. D. Cuny, M. Z. Hoemann, J. R. Hauske, and I. Chopra Biological Properties of Novel Antistaphylococcal Quinoline-Indole Agents Antimicrob. Agents Chemother., February 1, 2003; 47(2): 458 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill, J. M. Bostock, A. Morais Moita, and I. Chopra Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid J. Antimicrob. Chemother., December 1, 2002; 50(6): 839 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill and I. Chopra Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low J. Antimicrob. Chemother., August 1, 2002; 50(2): 161 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miller, A. J. O'Neill, and I. Chopra Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes J. Antimicrob. Chemother., June 1, 2002; 49(6): 925 - 934. [Abstract] [Full Text] [PDF]
|
|